

## DAFTAR PUSTAKA

1. Shoji F. Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients. *Ann Transl Med.* 2020;8(11):668–73.
2. Yin JY, Li X, Li XP, Xiao L, Zheng W, Chen J, et al. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. *Cancer Lett.* 2016;377(1):65–73.
3. Min HY, Lee HY. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. *Arch Pharm Res* [Internet]. 2021;44(2):146–64. Available from: <https://doi.org/10.1007/s12272-021-01312-y>
4. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. *Nat Rev Cancer* [Internet]. 2021;21(6):345–59. Available from: <http://dx.doi.org/10.1038/s41568-021-00347-z>
5. Zhang Y, Chen B, Wang L, Wang R, Yang X. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. *Med (United States).* 2019;98(3):1–7.
6. Yilmaz M, Baran A, Yilmaz MK. Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy. *J Cancer Res Ther* [Internet]. 2022;18(1):220–3. Available from: 10.4103/jert.jert\_1902\_20
7. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. *J Transl Med.* 2017;15(1):1–10.
8. Jusuf A, Wibawanto A, Icksan AG, Syahrudin E, Juniarti, Endardjo S. *Kanker paru*. 1st ed. Syahrudin E, Jusuf A, editors. Jakarta: UI-Press; 2018. h. 1-37.
9. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. *Transl Lung Cancer Res.* 2015;4(4):327–38.
10. Sembiring R, Hidajat H, Jusuf A, Jonathan S. Klasifikasi histologis kanker paru. In: Jusuf A, editor. *Dasar-dasar diagnosis kanker paru*. 1st ed. Jakarta: UI-Press; 2017. p. 89–101.
11. Wati FF. *Kanker paru*. In: Amin M, K W, Hasan H, Marhana IA, editors. *Buku ajar paru*. 1st ed. Surabaya: Airlangga University Press; 2019. p. 125–45.
12. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J Thorac Oncol* [Internet]. 2022;17(3):62–387. Available from: <https://doi.org/10.1016/j.jtho.2021.11.003>
13. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, et al. Diagnostic, predictive and prognostic biomarkers in non-small cell lung cancer (NscLc) management. *J Pers Med.* 2021;11(11):1–27.
14. Alatas MF, Putra AC, Andarini S, Sutoyo DK, Loura T. *Imunologi kanker paru*. In: Jusuf A, editor. *Dasar-dasar diagnosis kanker paru*. 1st ed. Jakarta: UI-Press; 2017. p. h. 113-25.

15. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, et al. Immune cell composition in human Non-small Cell Lung Cancer. *Front Immunol.* 2019;9(February):1–21.
16. Wang C, Jin S, Xu S, Cao S. High Systemic Immune-Inflammation Index (SII) represents an unfavorable prognostic factor for small cell lung cancer treated with etoposide and platinum-based chemotherapy. *Lung [Internet].* 2020;198(2):405–14. Available from: <https://doi.org/10.1007/s00408-020-00333-6>
17. Xu S, Cao S, Yu Y. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis. *J Cancer Res Ther.* 2021;17(7):1636–42.
18. Brostjan C, Oehler R. The role of neutrophil death in chronic inflammation and cancer. *Cell Death Discov [Internet].* 2020;6(26):1–8. Available from: <http://dx.doi.org/10.1038/s41420-020-0255-6>
19. Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. *Platelets [Internet].* 2018;29(6):569–73. Available from: <https://doi.org/10.1080/09537104.2018.1453059>
20. Jusuf A, Hudoyo A, Syahrudin E. *Pengobatan kanker paru.* 1st ed. Jusuf A, editor. Jakarta: Perhimpunan Dokter Paru Indonesia; 2019. h. 1-162.
21. Syahrudin E, Zaini J, Soehardiman D, Anwidyarningsih W, Icksan AG, Mety SH, et al. *Kanker paru: Pedoman penstagingan dan pengevaluasian hasil terapu di Indonesia.* 1st ed. Syahrudin E, editor. Jakarta: Perhimpunan Dokter Paru Indonesia; 2019. h. 1-31.
22. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group Trials. *J Clin Oncol.* 2008;26(1):54–9.
23. Syahrudin E, Marlina N, Hudoyo A. Efikasi dan toksisitas rejimen sisplatin + etoposid untuk kemoterapi kanker paru jenis Karsinoma Bukan Sel Kecil (KPKBSK) Stage Lanjut. *Respir Indon.* 2012;32(1):h. 25-35.
24. Chen J, Shao J, Zhang X, Wei S, Cai H, Wang G. Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer. *Ann Transl Med.* 2022;10(5):1–13.
25. Tian T, Lu J, Zhao W, Wang Z, Xu H, Ding Y, et al. Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population. *Cancer Med.* 2022;11(12):2482–91.
26. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* 2014;20(23):6212–22.
27. Fest J, Ruiter R, Mulder M, Groot Koerkamp B, Ikram MA, Stricker BH, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer—A population-based cohort study. *Int J Cancer.* 2020;146(3):692–8.
28. Wang Y, Li Y, Chen P, Xu W, Wu Y, Che G. Prognostic value of the pretreatment

- systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. *Ann Transl Med.* 2019;7(18):1–9.
29. Guo W, Cai S, Zhang F, Shao F, Zhang G, Zhou Y, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. *Thorac Cancer.* 2019;10(4):761–8.
  30. Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. *Clin Chim Acta [Internet].* 2018;484(February):p.272-7. Available from: <https://doi.org/10.1016/j.cca.2018.05.059>
  31. Deng C, Zhang N, Wang Y, Jiang S, Lu M, Huang Y, et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. *Med (United States).* 2019;98(33):1–7.
  32. Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. *J Clin Lab Anal.* 2019;33(8):1–8.
  33. Song M, Zhang Q, Song C, Liu T, Zhang X, Ruan G, et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. *J Cachexia Sarcopenia Muscle.* 2022;1(March):1–11.
  34. Zhang Y, Chen Z, Jin F, Guo D, Chen Q, Liu Z, et al. The value of the systemic immune-inflammation index in predicting survival outcomes in patients with brain metastases of non-small-cell lung cancer treated with stereotactic radiotherapy. *Mediators Inflamm.* 2021;21(10):1–10.
  35. Nayak R, Rai S. *Rapid Review of Hematology [Internet].* 1st ed. Nayak R, editor. New Delhi: Jaypee Brothers Medical Publishers; 2014. p. 50-110. Available from: [https://books.google.co.id/books?id=H2%5C\\_doAEACAAJ](https://books.google.co.id/books?id=H2%5C_doAEACAAJ)
  36. Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. *Ann Transl Med.* 2019;7(20):572–81.
  37. Sastroasmoro S. *Dasar-dasar Metodologi Penelitian Klinis.* 5th ed. Sastroasmoro S, Ismael S, editors. Vol. 5. Jakarta: Sagung Seto; 2018. h. 352-86.
  38. Cao M, Chen W. Epidemiology of lung cancer in China. *Thorac Cancer.* 2019;10(1):3–7.
  39. Thandra K, Barsouk A, Saginala K, Aluru J, Barsouk A. Epidemiology of lung cancer. *Contemp Oncol.* 2021;25(1):45–52.
  40. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. *J Cancer Res Clin Oncol [Internet].* 2020;146(1):43–52. Available from: <https://doi.org/10.1007/s00432-019-03079-8>
  41. Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. *Ann Transl Med.* 2019;7(20):p.572-81.
  42. Vinas F, Ben Hassen I, Jabot L, Monnet I, Chouaid C. Delays for diagnosis and

treatment of lung cancers: A systematic review. *Clin Respir J.* 2016;10(3):267–71.

43. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomi. *Lung Cancer.* 2008;59(1):1–11.
44. Xu S, Cao S, Yu Y. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis. *J Cancer Res Ther.* 2021;17(7):p.1636-
45. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. *J Transl Med.* 2017;15(1):p.1-10.

